ProMIS Neurosciences : Corporate Overview

ProMIS Neurosciences Overview

Targeting Misfolded Proteins in Neurodegenerative Diseases

NASDAQ: PMN

Toronto Stock Exchange (TSX): PMN.TO

January 31, 2023

1

Legal Disclaimers

This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on ProMIS Neurosciences Inc.'s (the "Company") current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this slide deck. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings available online at sec.govand sedar.com, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2

Experienced Leadership Team

Executive Management

Gail Farfel, Ph.D.	Neil Cashman, M.D.	Johanne Kaplan, Ph.D.	Larry Altstiel, M.D., Ph.D.
Chief Executive Officer	Chief Scientific Officer	Chief Development Officer	Chief Medical Officer

Gavin Malenfant	David Wishart, Ph.D.	Dan Geffken
Chief Operating Officer	Chief Physics Officer	Chief Financial Officer

Board of Directors

Eugene Williams, M.B.A.	Neil Cashman, M.D.	Gail Farfel, Ph.D.*	Richard Gregory, Ph.D.
Chairman and Co-founder	Chief Scientific Officer and Co-founder	Chief Executive Officer	Independent Director
Patrick Kirwin, B.A., J.D.	Josh Mandel-Brehm, M.B.A.	Maggie Shafmaster, Ph.D., J.D.	Neil K. Warma, M.B.A., B.Sc.	William Wyman, M.B.A.
Independent Director	Independent Director	Lead Independent Director	Independent Director		Independent Director

* observer	3

Developing the) Next Generation Disease-Modifying Treatment for

Alzheimer's Disease

ProMIS Platform

Technology

PMN310 in Alzheimer's

Disease

PMN310 Entering Clinical

Phase

• Proprietary computational platform generates antibodies selective for toxic misfolded proteins driving disease in CNS
• Humanized IgG1 antibody selective for misfolded, toxic Aβ oligomers → expected to be more potent with no ARIA
• Phase 1a data mid-2023 will support safety, dose selection for Alzheimer's patient 1b study

PMN310 Advantage

• Selectivity for toxic oligomers expected to boost effective dose reaching the target
• Lack of plaque binding avoids ARIA, a dose-limiting adverse event

4

ProMIS Discovery Platform:

Physics + Biology + Supercomputing = Differentiation

PHYSICS:

Protein folding

BIOLOGY:

Proteins: toxic or normal

SUPERCOMPUTING:

Protein shape can only be assessed computationally

PROMIS

DISCOVERY

PLATFORM

ANTIBODIES HIGHLY SELECTIVE FOR TOXIC MISFOLDED PROTEINS

5